TRENDING :  Market Movers  |  Top 50   AMD (0%)    NFLX (0%)    SPY (0%)    SPX (0%)    DGAZ (0%)    TSLA (0%)    UGAZ (0%)    VXXB (0%)    VXX (0%)    TWLO (0%)    TLT (0%)    SQQQ (0%)    BOIL (0%)    BABA (0%)    SM (0%)    PCG (0%)    NBEV (0%)    MNGA (0%)    MBOT (0%)    INPX (0%)

 NKTR - Nektar Therapeutics

$45.42 (0%)

Next Earnings

2/28/2019

AMC



Analyst Rating

Quarterly Rating Chart
Rating

2


1=Strong Buy, 2=Buy, 3=Hold, 4=Underperform, 5=Sell
Price Targets
High $86.00
Low $62.00
Average $73.67
Current $45.42

CompanyAnalyst NamePT ActionActionRatingTargetDate
Goldman SachsAnnouncesInitiates Coverage OnBuy$62.0012/13/18
Canaccord GenuityArlinda LeeLowersMaintainsBuy$86.0011/13/18
JefferiesLowersMaintainsBuy$73.0011/08/18
*Last 90 days

OPEN RECOMMENDATIONS

No recommendations found.


This list is limited to recommendations made in last 7 days only. Subscribe to a service to see all their recommendations.

TRADERS TRACKING $NKTR

TRENDING ARTICLES



Here's Why Nektar Therapeutics Gave Back 45% in 2018

01/15/19
What happened Shares of Nektar Therapeutics NASDAQ NKTR 160 a biopharmaceutical company fell 45 in 2018 according to data from S amp P Global Market Intelligence Despite the company signing a lucrative collaboration deal less than thrilling immuno oncology

Here's Why Nektar Therapeutics Surged Today

01/09/19
What happened Shares of Nektar Therapeutics NASDAQ NKTR a biopharmaceutical company are on the move following its presentation at the J P Morgan Healthcare conference The stock climbed 11 1 during Tuesday s session as investors cheered Nektar s 2019 to do list So

Nektar To Present At J.P. Morgan Conference; Webcast At 12:00 PM ET

01/08/19
Nektar To Present At J.P. Morgan Conference; Webcast At 12:00 PM ET

S&P 500 Movers: PCG, MAT

01/07/19
In early trading on Monday shares of Mattel MAT topped the list of the day s best performing components of the S amp P 500 index trading up 5 7 Year to date Mattel registers a 10 2 gain And the worst performing S amp P 500 component thus far on the day is PG amp E Corp

Nektar, ImaginAb Enter Into Immuno-Oncology Collaboration

01/04/19
Nektar Therapeutics NKTR has entered into a non exclusive license and clinical trial collaboration with privately held ImaginAb Inc to support its immuno oncology pipeline The deal will allow Nektar to use ImaginAb s CD8 ImmunoPET technology which measures the density and distribution of

ImaginAb Reaches ImmunoOncology License&Clinical Trial Collaboration With Nektar

01/03/19
ImaginAb Reaches ImmunoOncology License&Clinical Trial Collaboration With Nektar

S&P 500 Movers: LNT, NKTR

01/02/19
In early trading on Wednesday shares of Nektar Therapeutics NKTR topped the list of the day s best performing components of the S amp P 500 index trading up 2 3 Year to date Nektar Therapeutics registers a 2 3 gain And the worst performing S amp P 500 component thus far on the

BioXcel Surges on Fast Track Designation to Agitation Drug

12/28/18
Shares of clinical stage biopharmaceutical company BioXcel Therapeutics Inc BTAI surged significantly after the FDA granted Fast Track designation to its experimental drug BXCL501 BXCL501 a proprietary sublingual film of dexmedetomidine is being evaluated for the treatment of

3 Top Biotech Stocks to Buy Right Now

12/28/18
Biotechnology is a notoriously difficult industry to invest in Companies live or die based on the strength of their patents and the speed and impact of their innovations and there are very few sure bets from an investment perspective among the businesses that operate within